Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$42.25-3.3%$34.96$2.81▼$47.84$2.63B2.32964,416 shs162,041 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences-4.82%+0.46%+4.52%+89.58%+1,029.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKODKodiak Sciences$42.25-3.3%$34.96$2.81▼$47.84$2.63B2.32964,416 shs162,041 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKODKodiak Sciences-4.82%+0.46%+4.52%+89.58%+1,029.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKODKodiak Sciences 2.50Moderate Buy$35.43-18.89% DownsideCurrent Analyst Ratings BreakdownLatest ARV, KOD, MKA, and HE1 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2026KODKodiak Sciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.003/27/2026KODKodiak Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00 ➝ $58.002/10/2026KODKodiak Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKODKodiak Sciences-$229.97M-$4.32N/AN/AN/AN/A-255.37%-81.82%5/13/2026 (Estimated)Latest ARV, KOD, MKA, and HE1 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKODKodiak SciencesN/A4.724.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipKODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKODKodiak Sciences9062.16 million33.63 millionOptionableKDNC, 1SN, KOD, and AFRK HeadlinesRecent News About These CompaniesKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsMay 7 at 4:00 PM | prnewswire.comKodiak Sciences (KOD) Expected to Announce Earnings on WednesdayMay 6 at 7:21 AM | marketbeat.comKodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLCMay 3, 2026 | marketbeat.comKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesApril 30, 2026 | prnewswire.comKodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?April 30, 2026 | zacks.comKodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?April 24, 2026 | finance.yahoo.comKodiak Sciences Inc. (NASDAQ:KOD) Receives Average Recommendation of "Moderate Buy" from BrokeragesApril 21, 2026 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Hits New 12-Month High - What's Next?April 20, 2026 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Stock Price Up 9.8% - What's Next?April 17, 2026 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Signals Behind Surge Points To MomentumApril 16, 2026 | kalkinemedia.comKKodiak Sciences Inc. (NASDAQ:KOD) Short Interest Up 39.8% in MarchApril 15, 2026 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Stock Price Down 5.5% - Should You Sell?April 15, 2026 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Hits New 52-Week High - Here's What HappenedApril 13, 2026 | marketbeat.comKodiak Sciences (KOD) reports Q4 EPS of ($1.05)April 12, 2026 | msn.comKodiak Sciences (KOD) price target increased by 56.62% to 56.71April 10, 2026 | msn.comJ.P. Morgan Reaffirms Their Buy Rating on Kodiak Sciences (KOD)April 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kodiak Sciences (KOD)April 8, 2026 | theglobeandmail.comKodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In FocusApril 7, 2026 | finance.yahoo.comAssessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting SignalsApril 6, 2026 | finance.yahoo.comZenkuda superior to sham in phase 3 diabetic retinopathy studyApril 3, 2026 | healio.comHKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial ResultsApril 1, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026KDNC, 1SN, KOD, and AFRK Company DescriptionsKodiak Sciences NASDAQ:KOD$42.25 -1.43 (-3.27%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
